Zacks
Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year?
📈
AI Sentiment
Highly Positive
9/10
- Home
- AUPH
as of 01-02-2026 12:46pm EST
$15.20
$0.75
-4.73%
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
| Founded: | 1993 | Country: | Canada |
| Employees: | N/A | City: | EDMONTON |
| Market Cap: | 1.6B | IPO Year: | 1999 |
| Target Price: | $17.25 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.55 - $16.54 | Next Earning Date: | 11-04-2025 |
| Revenue: | $265,808,000 | Revenue Growth: | 20.62% |
| Revenue Growth (this year): | 21.76% | Revenue Growth (next year): | 16.45% |
AI-Powered AUPH Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 67.74%
67.74%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Aurinia Pharmaceuticals Inc News
AUPH Breaking Stock News: Dive into AUPH Ticker-Specific Updates for Smart Investing
Compare AUPH vs Leading Stocks
See how AUPH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AUPH Aurinia Pharmaceuticals Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.